Literature DB >> 12561056

Metabolic disorders and mental retardation.

Stephen G Kahler1, Michael C Fahey.   

Abstract

The metabolic and anatomical substrate of most forms of mental retardation is not known. Because the basis of normal brain function is not sufficiently understood, the basis of abnormal function is understood poorly. Even in disorders where the fundamental biochemical defect is known, such as phenylketonuria (PKU) and other enzyme defects, the exact basis for brain dysfunction is uncertain. The outcome for treated PKU, galactosemia, homocystinuria, and lysosomal disorders is not yet optimal. The various forms of nonketotic hyperglycinemia often respond poorly to current therapy. Less familiar disorders, with or without seizures, such as deficient synthesis of serine or creatine and impaired glucose transport into the brain, and disorders with variable malformations, such as Smith-Lemli-Opitz (SLO) syndrome and the congenital disorders of glycosylation (CDGs), may initially be thought to be a nonspecific form of developmental delay. Less familiar disorders, with or without seizures and disorders with variable malformations may initially be thought to be a nonspecific form of developmental delay. Simple tests of urine, blood, and cerebrospinal fluid may lead to a diagnosis, accurate genetic counseling, and better treatment. Metabolic brain imaging (magnetic resonance spectroscopy (MRS)) has also helped to reveal biochemical abnormalities within the brain. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12561056     DOI: 10.1002/ajmg.c.10018

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  13 in total

1.  Retention and loss of amino acid biosynthetic pathways based on analysis of whole-genome sequences.

Authors:  Samuel H Payne; William F Loomis
Journal:  Eukaryot Cell       Date:  2006-02

Review 2.  When to suspect a genetic syndrome.

Authors:  Benjamin D Solomon; Maximilian Muenke
Journal:  Am Fam Physician       Date:  2012-11-01       Impact factor: 3.292

3.  Effects of creatine and β-guanidinopropionic acid and alterations in creatine transporter and creatine kinases expression in acute seizure and chronic epilepsy models.

Authors:  Dae Won Kim; Seong-Il Yeo; Hea Jin Ryu; Ji-Eun Kim; Hong-Ki Song; Oh-Shin Kwon; Soo Young Choi; Tae-Cheon Kang
Journal:  BMC Neurosci       Date:  2010-10-28       Impact factor: 3.288

4.  Dysmorphology diagnosis.

Authors:  Ratna Dua Puri; I C Verma
Journal:  Indian J Pediatr       Date:  2004-06       Impact factor: 1.967

5.  Brain-derived neurotrophic factor inhibits phenylalanine-induced neuronal apoptosis by preventing RhoA pathway activation.

Authors:  Yongjun Zhang; Jing Zhao; Jing Wang; Xianting Jiao
Journal:  Neurochem Res       Date:  2009-11-05       Impact factor: 3.996

6.  Temporal and regional differences in the olfactory proteome as a consequence of MeCP2 deficiency.

Authors:  Valéry Matarazzo; Gabriele V Ronnett
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-05       Impact factor: 11.205

Review 7.  Mental retardation and inborn errors of metabolism.

Authors:  A García-Cazorla; N I Wolf; M Serrano; U Moog; B Pérez-Dueñas; P Póo; M Pineda; J Campistol; G F Hoffmann
Journal:  J Inherit Metab Dis       Date:  2009-08-14       Impact factor: 4.982

8.  A long-term study of bone mineral density in patients with phenylketonuria under diet therapy.

Authors:  Hala M Koura; Nagwa Abdallah Ismail; Ashraf F Kamel; Azza M Ahmed; Amal Saad-Hussein; Laila K Effat
Journal:  Arch Med Sci       Date:  2011-07-11       Impact factor: 3.318

9.  The Association between EEG Abnormality and Behavioral Disorder: Developmental Delay in Phenylketonuria.

Authors:  Parvaneh Karimzadeh; Mohammad Reza Alaee; Hadi Zarafshan
Journal:  ISRN Pediatr       Date:  2012-03-29

10.  Peak bone mass in patients with phenylketonuria.

Authors:  D Modan-Moses; I Vered; G Schwartz; Y Anikster; S Abraham; R Segev; Ori Efrati
Journal:  J Inherit Metab Dis       Date:  2007-03-08       Impact factor: 4.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.